FDA staff report due out today on GSK's Avandia

FDA staff report due out today on diabetes drug: "'There is a broader context here because there are a number of very vocal critics of the drug,' said Les Funtleyder, portfolio manager and health care strategist at investment firm Miller Tabak. 'There have been a number of drug recalls, so the FDA is likely to be quite cautious.'

- Sent using Google Toolbar"